Promising Advancements and Strategic Developments Drive Buy Rating for Purple Biotech

In a report released yesterday, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Purple Biotech, with a price target of $34.00.

Emily Bodnar’s rating is based on Purple Biotech’s promising advancements in their tribody programs, particularly the development of IM1305 and IM1240. The IM1305 tribody has shown encouraging preclinical results, demonstrating sustained tumor regression in a TNBC mouse model without recurrence, which suggests potential effectiveness in a wider range of TROP2-expressing tumors. Additionally, the company’s collaboration with the Icahn School of Medicine at Mt. Sinai on IM1240 has yielded promising preclinical data, indicating antitumor activity in patient-derived samples of anti-PD-1 resistant head and neck squamous cell carcinoma.
Furthermore, Purple Biotech has established a scalable manufacturing process for IM1240, which is a positive step towards its planned IND submission and first-in-human trials. The company’s strategic focus on its CAPTN-3 platform could facilitate additional pipeline programs, licensing deals, or acquisitions, enhancing its growth potential. While the tribody programs are still in the preclinical stage, the promising data and strategic developments contribute to the Buy rating, as they indicate potential for future success and expansion.